PDS Biotechnology Corporation Finalizes Commercial Licensing Agreement with Merck Eprova AG to Utilize Merck Eprova's Enantiomers of DOTAP Chloride in Immunotherapies



    INDIANAPOLIS, Feb. 24 /CNW/ -- PDS Biotechnology today announced that the
company has obtained an exclusive license from Merck Eprova AG to utilize
Merck Eprova's proprietary chiral lipid DOTAP Chloride in Versamune(TM)-HPV
and other products in development based on the Versamune(TM) technology.  The
use of enantiomerically pure DOTAP Chloride shows enhanced adjuvant activity
compared to the racemate.  Merck Eprova AG will be providing enantiomerically
pure DOTAP Chloride manufactured under cGMP for use in clinical and commercial
drug products developed with PDS Biotechnology's Versamune(TM) nanoparticle
technology.  PDS Biotechnology will own the intellectual property rights to
products incorporating the chiral DOTAP lipids for immunotherapeutic
applications.
    Versamune(TM)-HPV is an immunotherapy drug which has demonstrated
significant promise in curing HPV infection and HPV-related cancer in
preclinical animal and human model studies.  Cancers caused by infection with
the human papilloma virus (HPV) include cervical, head and neck and anal
cancers.  No cures exist for these cancers.  Based on promising in vivo and in
vitro efficacy data, PDS Biotechnology has been awarded grants by the US
National Institutes of Health/National Cancer Institute to develop
Versamune(TM)-HPV and Versamune(TM)-Melanoma. Versamune(TM)-Melanoma is being
developed to treat melanoma, which is the most aggressive form of skin cancer.
    PDS Biotechnology's Versamune(TM) nanotechnology facilitates the uptake
of disease-associated protein and peptide antigens by the antigen-presenting
cells of the immune system. Simultaneously it acts as a strong immune system
activator (adjuvant) without the inflammatory side effects induced by current
adjuvants.  The result is simple, safe and cost effective nanotechnology-based
drugs and vaccines that induce effective eradication of the specific cells
infected with, or expressing the particular protein formulated with
Versamune(TM).
    PDS Biotechnology Corporation (www.pdsbiotech.com) is an Indiana-based
biotechnology company applying the company's proprietary Versamune(TM)
nanotechnology drug platform technology to the development of safe and potent
immunotherapies to prevent and to treat cancer and diseases caused by
infectious agents.
    Merck Eprova AG (www.merckeprova.com), located in Schaffhausen,
Switzerland, is a wholly owned subsidiary of Merck KGaA located in Darmstadt,
Germany.  Merck Eprova AG specializes in the development and production of
cGMP grade, highly purified and characterized Drug Delivery Compounds such as
cationic lipids, PEGs, PEG-lipids, and phospholipids.  In addition Merck
Eprova AG is a centre of excellence for reduced folates in the pharmaceutical
and nutritional field and the world's leading supplier of reduced folates.




For further information:

For further information: Frank Bedu-Addo of PDS Biotechnology,
+1-513-807-6840 Web Site: http://www.pdsbiotech.com                
http://www.merckeprova.com

Organization Profile

PDS BIOTECHNOLOGY

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890